Cost Offset Associated With Early Start Denver Model for Children With Autism - 23/08/17
, Jeff Munson, PhD b, Annette Estes, PhD b, Geraldine Dawson, PhD c, Sally Rogers, PhD d, David Mandell, ScD aAbstract |
Objective |
To determine the effect of the Early Start Denver Model (ESDM) for treatment of young children with autism on health care service use and costs.
Method |
We used data from a randomized trial that tested the efficacy of the ESDM, which is based on developmental and applied behavioral analytic principles and delivered by trained therapists and parents, for 2 years. Parents were interviewed about their children’s service use every 6 months from the onset of the intervention to follow-up (age 6 years). The sample for this study consisted of 39 children with autism who participated in the original randomized trial at age 18 to 30 months, and were also assessed at age 6 years. Of this sample, 21 children were in the ESDM group, and 18 children were in the community care (COM) group. Reported services were categorized and costed by applying unit hourly costs. Annualized service use and costs during the intervention and post intervention for the two study arms were compared.
Results |
During the intervention, children who received the ESDM had average annualized total health-related costs that were higher by about $14,000 than those of children who received community-based treatment. The higher cost of ESDM was partially offset during the intervention period because children in the ESDM group used less applied behavior analysis (ABA)/early intensive behavioral intervention (EIBI) and speech therapy services than children in the comparison group. In the postintervention period, compared with children who had earlier received treatment as usual in community settings, children in the ESDM group used less ABA/EIBI, occupational/physical therapy, and speech therapy services, resulting in significant cost savings in the amount of about $19,000 per year per child.
Conclusion |
Costs associated with ESDM treatment were fully offset within a few years after the intervention because of reductions in other service use and associated costs.
Clinical trial registration information: Early Characteristics of Autism; clinicaltrials.gov/; NCT0009415.
Le texte complet de cet article est disponible en PDF.Key words : autism, cost, use, Early Start Denver Model, early intervention
Plan
| This article is discussed in an editorial by Dr. Douglas L. Leslie on page 727. |
|
| The clinical trial was supported by National Institute of Mental Health grant U54MH066399 (Dawson, PI), which was registered at www.clinicaltrials.gov with identifier NCT00090415. Additional grants supported the long-term follow-up study (Estes, PI) funded by the National Institute of Child Health and Human Development (U19HD34565, P50HD066782, R01HD-55741), and the National Institute of Mental Health (U54MH066399). Autism Speaks also provided financial support. |
|
| Dr. Cidav conceptualized the study and its design, conducted the analyses, and drafted the initial manuscript. Dr. Munson assisted with the analyses, especially the coding of different service types, and assisted with interpretation of data. Dr. Estes oversaw original data collection for the follow-up study, and assisted with acquisition and interpretation of data. Dr. Dawson designed and oversaw the original randomized controlled trial and its data collection, and assisted with the acquisition of data and interpretation of data. Dr. Rogers provided training and consultation on the original randomized controlled trial and assisted with interpretation of data. Dr. Mandell helped draft the initial manuscript, and assisted with analysis and interpretation of data. All authors assisted with revising the manuscript for important intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. |
|
| Drs. Cidav and Munson served as the statistical experts for this research. |
|
| Disclosure: Dr. Dawson has served on the scientific advisory boards of Janssen Research and Development and Akili, Inc., as a consultant to Roche, and has received grant funding from Janssen Research and Development, LLC and PerkinElmer. She has received royalties from the sale of the Early Start Denver Model manuals, Guilford Press, and Oxford University Press. Dr. Rogers has received royalties from the sale of the Early Start Denver Model manuals. Dr. Mandell has served on the scientific advisory board of the Autism Science Foundation and serves as the editor-in-chief of Autism: The International Journal of Research and Practice, for which he receives a stipend. Drs. Cidav, Munson, and Estes report no biomedical financial interests or potential conflicts of interest. |
Vol 56 - N° 9
P. 777-783 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
